GlassScriptPhysician profile
Shetal M Mansuria
NPI 1902883788
$3,128.98
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,499 · 2020: $1,030 · 2022: $600.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $2,740.40 | 2019-2022 | |
| Allergan, INC. | $172.04 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $59.08 | 2019 | |
| Abbvie INC. | $36.56 | 2019-2020 | |
| Therapeuticsmd, INC. | $29.22 | 2019-2020 | |
| Exeltis, USA INC. | $24.74 | 2019-2020 | |
| Duchesnay USA Incorporated | $14.49 | 2019 | |
| Daiichi Sankyo INC. | $14.30 | 2019 | |
| Avion Pharmaceuticals | $13.46 | 2020 | |
| Amag Pharmaceuticals, INC. | $12.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shetal Mansuria listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.